Short Interest in Pulmatrix, Inc. (NASDAQ:PULM) Rises By 252.8%

Pulmatrix, Inc. (NASDAQ:PULM) saw a large increase in short interest in September. As of September 30th, there was short interest totaling 12,700 shares, an increase of 252.8% from the September 15th total of 3,600 shares. Based on an average daily trading volume, of 12,700 shares, the short-interest ratio is currently 1.0 days. Approximately 0.4% of the company’s stock are sold short. Approximately 0.4% of the company’s stock are sold short. Based on an average daily trading volume, of 12,700 shares, the short-interest ratio is currently 1.0 days.

Institutional Trading of Pulmatrix

A hedge fund recently raised its stake in Pulmatrix stock. SBI Securities Co. Ltd. lifted its position in Pulmatrix, Inc. (NASDAQ:PULM) by 15.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,565 shares of the biotechnology company’s stock after buying an additional 8,208 shares during the period. SBI Securities Co. Ltd.’s holdings in Pulmatrix were worth $418,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 11.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Pulmatrix Price Performance

Pulmatrix stock opened at $4.88 on Friday. The stock has a fifty day simple moving average of $4.82 and a two-hundred day simple moving average of $5.98. Pulmatrix has a 12 month low of $1.96 and a 12 month high of $10.40.

Pulmatrix (NASDAQ:PULM) last posted its earnings results on Thursday, October 16th. The biotechnology company reported ($0.24) EPS for the quarter.

About Pulmatrix

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.